Literature DB >> 9070991

Functional echoplanar brain imaging correlates of amphetamine administration to normal subjects and subjects with the narcoleptic syndrome.

R J Howard1, C Ellis, E T Bullmore, M Brammer, J D Mellers, P W Woodruff, A S David, A Simmons, S C Williams, J D Parkes.   

Abstract

Two subjects with narcoleptic syndrome and three healthy volunteers underwent functional magnetic resonance imaging during the simultaneous presentation of periodic auditory and visual stimuli both before and after administration of amphetamine. The effect of amphetamine in control subjects was a small reduction in the extent of sensory-induced activation. In the narcoleptic subjects, amphetamine led to an increase in the extent of induced activation within primary and association sensory cortex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9070991     DOI: 10.1016/s0730-725x(96)00238-x

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  4 in total

Review 1.  Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.

Authors:  C A Bryant; S H Jackson
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

2.  The influence of amphetamine on language activation: an fMRI study.

Authors:  Iris E C Sommer; Bob Oranje; Nick F Ramsey; Floris A Klerk; René C W Mandl; Herman G M Westenberg; René S Kahn
Journal:  Psychopharmacology (Berl)       Date:  2005-11-12       Impact factor: 4.530

Review 3.  Neuroimaging insights into the pathophysiology of sleep disorders.

Authors:  Martin Desseilles; Thanh Dang-Vu; Manuel Schabus; Virginie Sterpenich; Pierre Maquet; Sophie Schwartz
Journal:  Sleep       Date:  2008-06       Impact factor: 5.849

Review 4.  Functional magnetic resonance imaging in narcolepsy and the kleine-levin syndrome.

Authors:  Maria Engström; Tove Hallböök; Attila Szakacs; Thomas Karlsson; Anne-Marie Landtblom
Journal:  Front Neurol       Date:  2014-06-25       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.